GlassScriptPhysician profile
Crystal A Brown
NPI 1992162523
$8,712.99
in general payments reported to CMS, 2019-2025
27 companies · $1,828 in 2025
The $1,828 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,502 · 2022: $1,377 · 2023: $2,025 · 2024: $1,981 · 2025: $1,828.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,834.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,834.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,127.69 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,074.74 | 2021-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $1,028.40 | 2021-2025 | Stelara, Tremfya, Remicade |
| Regeneron Healthcare Solutions, INC. | $630.56 | 2022-2025 | Dupixent |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $324.11 | 2021-2025 | Xifaxan |
| Gilead Sciences, INC. | $269.23 | 2024-2025 | Livdelzi |
| Aimmune Therapeutics, INC. | $261.56 | 2024-2025 | Zenpep |
| Celgene Corporation | $260.43 | 2021-2024 | Zeposia |
| Nestle Healthcare Nutrition INC. | $222.52 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $215.85 | 2021-2024 | Dificid |
| Pfizer INC. | $187.52 | 2023-2024 | |
| Intercept Pharmaceuticals, INC. | $170.58 | 2021-2025 | Ocaliva |
| Genzyme Corporation | $140.92 | 2022-2024 | |
| Janssen Scientific Affairs, LLC | $98.94 | 2023 | Stelara |
| Madrigal Pharmaceuticals | $92.11 | 2025 | Rezdiffra |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $90.62 | 2023-2025 | Renflexis, Hadlima |
| Ardelyx, INC. | $76.08 | 2023-2025 | Ibsrela |
| Amgen INC. | $61.94 | 2023 | Amjevita, Avsola |
| Ferring Pharmaceuticals INC. | $60.79 | 2021-2023 | Rebyota |
| Redhill Biopharma INC. | $54.34 | 2021 | |
| Phathom Pharmaceuticals, INC. | $54.29 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $47.40 | 2025 | Omvoh |
| Ironwood Pharmaceuticals, INC | $41.96 | 2021-2024 | |
| Ipsen Biopharmaceuticals, INC | $39.92 | 2025 | Iqirvo |
| Enterra Medical, INC. | $33.59 | 2022 | |
| Braintree Laboratories, INC. | $26.06 | 2021 | |
| Medtronic, INC. | $20.84 | 2024 | Interstim |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Crystal Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.